
    
      A multicenter, randomized, double-blind, placebo controlled, parallel group study of
      eszopiclone 3 mg in subjects with insomnia related to rheumatoid arthritis. This study was
      previously posted by Sepracor Inc. In October 2009, Sepracor Inc. was acquired by Dainippon
      Sumitomo Pharma., and in October 2010, Sepracor Inc's name was changed to Sunovion
      Pharmaceuticals Inc.
    
  